Details of the trial, involving 23 patients, are to be reported at the annual meeting of the American Society of Clinical Oncology in May 2001.
Five patients showed tumor stabilization for up to six months - and one patient showed a period of tumor shrinkage, according to developers SafeScience of Boston, Massachusetts, USA.
The patients in the trial had late-stage disease, and had undergone other chemotherapy before testing the new drug, but had shown no response or had suffered a relapse.
|GBC-590 is a lectin inhibitor that interacts with the galectin-3 receptor.
During Phase IIb trials, investigators will test the effect of increased doses of the drug and seek to determine optimum dosage.
GBC-590 is a lectin inhibitor, which may be useful in treating cancer through interaction with the galectin-3 receptor. It is also being tested for the treatment of pancreatic cancer.
Researcher Dr Thomas Cartwright, Associate Chair of the Gastrointestinal Research Committee of US Oncology - the US nationwide chain of cancer centers - said, "I am impressed by the drug, even at this early phase. This could potentially be an effective therapeutic to treat colorectal cancer."
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com